Lemercier Jean-Luc M 4
4 · Edwards Lifesciences Corp · Filed May 1, 2024
Insider Transaction Report
Form 4
Lemercier Jean-Luc M
CVP, EMEA, Canada, Latin Amer
Transactions
- Exercise/Conversion
Common Stock
2024-05-01$36.75/sh+14,400$529,200→ 188,248.806 total - Sale
Common Stock
2024-05-01$84.11/sh−12,240$1,029,449→ 173,848.806 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2024-05-01−14,400→ 0 totalExercise: $36.75From: 2018-05-11Exp: 2024-05-10→ Common Stock (14,400 underlying) - Sale
Common Stock
2024-05-01$84.83/sh−2,160$183,238→ 186,088.806 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $84.750 to $84.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $83.740 to $84.725. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.